CIBINQO vs JAKAFI

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. CIBINQO and JAKAFI are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CIBINQO	JAKAFI
Rating	64/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	ABROCITINIB	RUXOLITINIB PHOSPHATE
Manufacturer	Pfizer	Incyte Corp
Dosage forms	Tablet	Tablet
Drug class	Janus Kinase Inhibitor	Janus Kinase Inhibitor
Boxed warning	Boxed warning	None
Treats	Atopic Dermatitis	Polycythemia Vera, Primary Myelofibrosis

cibinqo jakafi

Rating

64/100

New

Pharmacy pays

—

Type

Active ingredient

ABROCITINIB

RUXOLITINIB PHOSPHATE

Manufacturer

Pfizer

Incyte Corp

Dosage forms

Tablet

Drug class

Janus Kinase Inhibitor

Boxed warning

None

Treats

Atopic Dermatitis

Polycythemia Vera, Primary Myelofibrosis

Frequently asked questions

What is the difference between Cibinqo and Jakafi?

Cibinqo contains Abrocitinib, while Jakafi contains Ruxolitinib Phosphate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.